NAMI
AVIR icon

Nomura Asset Management International’s Atea Pharmaceuticals AVIR Stock Holding History

Nomura Asset Management International’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$326K Hold
70,000
– – ﹤0.01% 1290
2026
Q1 		$377K Hold
70,000
– – ﹤0.01% 1195
2025
Q4 		$250K Buy
+70,000
New +$222K ﹤0.01% 1216

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nomura Asset Management International's AVIR Position: Q2 2026 in Review

Nomura Asset Management International held its Atea Pharmaceuticals (AVIR) position steady in Q2 2026 at 70,000 shares worth $326K. The position accounts for ﹤0.01% of the portfolio, ranked #1290.

Nomura Asset Management International first reported a position in AVIR in Q4 2025 and has held it in 3 quarters since. The position peaked at $377K in Q1 2026. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Nomura Asset Management International held 70,000 shares of Atea Pharmaceuticals worth $326K as of Q2 2026.
  • Nomura Asset Management International left its Atea Pharmaceuticals share count unchanged in Q2 2026.
  • Atea Pharmaceuticals made up ﹤0.01% of Nomura Asset Management International's portfolio in Q2 2026, its #1290 holding.
  • Nomura Asset Management International first reported a position in Atea Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Nomura Asset Management International's Atea Pharmaceuticals position peaked at $377K in Q1 2026.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Nomura Asset Management International's 13F filing for Q2 2026, filed 14 Aug 2026.